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a b s t r a c t
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and hospi-
talization in infants and children globally. Many observational studies have found an association between
RSV LRTI in early life and subsequent respiratory morbidity, including recurrent wheeze of early child-
hood (RWEC) and asthma. Conversely, two randomized placebo-controlled trials of efficacious anti-RSV
monoclonal antibodies (mAbs) in heterogenous infant populations found no difference in physician-
diagnosed RWEC or asthma by treatment group. If a causal association exists and RSV vaccines and
mAbs can prevent a substantial fraction of RWEC/asthma, the full public health value of these interven-
tions would markedly increase. The primary alternative interpretation of the observational data is that
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RSV LRTI in early life is a marker of an underlying predisposition for the development of RWEC and
asthma. If this is the case, RSV vaccines and mAbs would not necessarily be expected to impact these out-
comes. To evaluate whether the available evidence supports a causal association between RSV LRTI and
RWEC/asthma and to provide guidance for future studies, the World Health Organization convened a
meeting of subject matter experts on February 12–13, 2019 in Geneva, Switzerland. After discussing rel-
evant background information and reviewing the current epidemiologic evidence, the group determined
that: (i) the evidence is inconclusive in establishing a causal association between RSV LRTI and RWEC/
asthma, (ii) the evidence does not establish that RSV mAbs (and, by extension, future vaccines) will have
a substantial effect on these outcomes and (iii) regardless of the association with long-term childhood
respiratory morbidity, severe acute RSV disease in young children poses a substantial public health bur-
den and should continue to be the primary consideration for policy-setting bodies deliberating on RSV
vaccine and mAb recommendations. Nonetheless, the group recognized the public health importance
of resolving this question and suggested good practice guidelines for future studies.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY IGO license.
(http://creativecommons.org/licenses/by/3.0/igo/).
1. Background and meeting objectives
Respiratory syncytial virus (RSV) is a leading cause of lower res-
piratory tract infection (LRTI) and hospitalization in children glob-
ally, causing an estimated 33.1 million LRTI episodes, 3.2 million
hospitalizations, and 118,000 deaths in 2015 [1]. An estimated
45% of all hospitalizations and deaths are in infants less than
6 months of age, with 99% of global RSV mortality occurring out-
side of North America and Europe. The only licensed monoclonal
antibody (mAb) to prevent RSV LRTI (Synagis, palivizumab) is rec-
ommended only in high-risk infants (e.g. preterm or with certain
co-morbidities) and is cost prohibitive for low and middle-
income countries (LMICs). There are no licensed vaccines for
RSV; however, several candidate products (e.g., vaccines and
mAbs) are in clinical development [2].
A long-standing question is whether RSV LRTI in early life
causes subsequent recurrent wheeze of early childhood (RWEC)
and asthma. The current evidence supporting a causal association
between RSV and RWEC/asthma is mixed. Understanding whether
prevention of RSV LRTI can lead to reductions in rates of RWEC and
asthma will contribute important information to policy decisions
regarding RSV vaccines and mAbs.
To shed light on this important question, the World Health
Organization (WHO) undertook three activities. The first com-
prised an analysis of the sample size required to estimate the
potential impact of RSV prevention by vaccines or mAbs on the
subsequent development of RWEC in RCTs [3]. The second was a
systematic review and meta-analysis that will be reported sepa-
rately. Third was a convening of subject matter experts on Febru-
ary 12–13, 2019 in Geneva, Switzerland (Agenda and Participants
in Appendix A). The objectives of the meeting were: (i) to evaluate
the strength of the current evidence for a causal association
between early life RSV LRTI and subsequent RWEC/asthma, (ii) to
evaluate the evidence that future RSV vaccines/mAbs can reduce
rates of RWEC/asthma, and (iii) to provide methodological guid-
ance for future studies. This report summarizes the meeting.
2. Epidemiology of RSV LRTI
Epidemiological studies have shown that more than half of chil-
dren experience their first RSV infection in the first 12 months of
life and almost all will have had an infection by two years of age
[4]. Involvement of the lower airways occurs in 15–50% of children
with primary RSV infection, with 45% of LRTI occurring in the first
6 months of life [1,5]. Although children born preterm, with low
birth weight, chronic lung disease, congenital heart disease, or
immunosuppression have increased risk of severe disease, most
children with RSV LRTI were born full-term and have no underly-
ing illnesses [6,7]. RSV LRTI usually corresponds to a clinical
diagnosis of bronchiolitis or pneumonia and is differentiated from
RSV upper respiratory tract infection by lower chest wall indraw-
ing, tachypnea, diffuse rhonchi, or wheezing [8]. Wheezing associ-
ated with the acute RSV LRTI episode can persist for up to 4 weeks
(median 12 days) [9]. The case-fatality ratio for RSV LRTI is low
(<1%) if a child receives supportive care in a timely manner, but
can be as high as 9% in low-income countries [1].
3. Epidemiology of RWEC and childhood asthma
Wheeze, which can refer to both a clinical sign and a reported
symptom, is an intrathoracic sound and a sign of airflow limitation
[10]. A large proportion of young children experience viral-
associated recurrent wheezing, a highly heterogenous condition
that is not always indicative of asthma [11]. Asthma represents a
disease spectrum with multiple phenotypes and may present with
respiratory signs and symptoms including wheeze. A clinical diag-
nosis of asthma in older children and adults requires a history of
symptom patterns and evidence of variable expiratory airflow lim-
itation, which can be assessed by different lung function testing
methods [11]. Asthma has been identified by WHO as one of the
most significant non-communicable diseases in people of all ages
and a major source of global economic burden, with the highest
rates of asthma mortality occurring in LMICs [12]. Estimates of glo-
bal childhood asthma prevalence come from the International
Study of Asthma and Allergies in Childhood (ISAAC), which uses
a standardized questionnaire for parent-reported history of
wheeze [13]. Latin America, North America and Australia/New
Zealand have the highest asthma prevalence among children 6–
7 years (17–22%), but it is believed that there are high rates of
undiagnosed asthma globally [14].
According to the Global Initiative for Asthma, asthma can be
challenging to diagnose in children less than six years of age for
the following reasons: (1) many young children experience viral-
associated recurrent wheezing in the absence of asthma, and (2)
measurements of airway obstruction using spirometry are chal-
lenging to perform in this age group and can be normal between
symptomatic episodes [11,15]. Global guidelines therefore recom-
mend that asthma diagnosis in children less than six years of age
be based on the presence of risk factors (e.g., family history of
asthma/atopy, allergic sensitization) in combination with respira-
tory symptom patterns, response to therapeutic treatment trials,
and the exclusion of alternate diagnoses [11]. As an alternative to
spirometry, the forced oscillation technique (FOT) to measure res-
piratory system resistance and compliance has recently been
shown to be a promising technique for the measurement of lung
function in children as young as six weeks [16].
Asthma is believed to be caused by complex interactions
between genes and the environment. Heritability estimates for
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asthma range from 25 to 95% and numerous markers of asthma
risk have been identified, most notably polymorphisms at the chro-
mosome 17q21 locus [17,18]. Variable asthma prevalence among
genetically similar populations living in different settings indicates
that environmental influences are key in asthma development
[19,20], and some environmental risk factors for asthma appear
to have the greatest effects in individuals with specific genetic risk
variants [21,22].
4. Biologic basis for an association between early life RSV LRTI
and RWEC/asthma
An association between infant bronchiolitis and later develop-
ment of asthma was first hypothesized in the late 1950 s [23].
Subsequent experimental studies have shown that mice infected
with RSV have sustained airway hyperreactivity and histologic
changes characteristic of human asthma that persist after
clearance of the virus [24], and that early life RSV infection impairs
regulatory T-cell function and increases susceptibility to allergic
airway disease [25,26]. In humans, increased RSV viral load [27]
and disease severity [28–30] are associated with increased risk of
RWEC and/or asthma in some studies but not in others [31,32].
In one infant cohort, a distinct nasal immune response pattern to
acute RSV illness was associated with increased risk of subsequent
wheeze [33].
It is not well understood why some otherwise healthy infants
develop severe LRTI when infected with RSV. Potential explana-
tions include infection with a more virulent RSV strain (37–39),
an aberrant host immune response [34], and/or the presence of
other pre-existent determinants of vulnerability, both genetic
and environmental (e.g. smoke exposure in utero and early life,
crowding, and day care attendance). If pre-existent determinants
of vulnerability cause severe disease with RSV infection, it is possi-
ble that they may also be independently predictive of an increased
risk of developing RWEC and asthma in childhood. Evidence in sup-
port of this theory is provided by a prospective cohort study that
assessed passive respiratory mechanics after birth, prior to any
LRTI event, and found lower lung compliance and higher resistance
to be associated with increased risk for both RSV hospitalization
and number of days with subsequent wheeze in the first year of life
[35]. Host genetic studies of RSV illness ascribe a genetic compo-
nent to risk for severe infection [36] and several shared markers
of risk for both RSV LRTI and asthma have been identified
[17,37,38]. Twin studies also suggest a shared genetic risk for both
diseases [39–41].
5. Evidence for an association between early life RSV LRTI and
RWEC/asthma
5.1. Observational studies
Most of the evidence for an association between early life RSV
LRTI and subsequent RWEC and asthma comes from observational
studies, of which only two have been conducted in LMICs [42,43].
These studies can be divided into two types: prospective studies
that follow longitudinal cohorts of children forward in time,
assessing them regularly for RSV LRTI and RWEC/asthma, and ret-
rospective studies that use administrative databases to identify
children who have had documented RSV LRTI and/or RWEC/
asthma in the past.
The first type of prospective study is referred to here as a ‘‘med-
ical event cohort study,” which defines exposure as an RSV LRTI
inpatient or outpatient medical event, usually occurring within
the first 1–2 years of life. Eligibility for enrollment into medical
event cohort studies is therefore defined based on the known
RSV LRTI exposure status. When studies compare this exposed
group to those without RSV LRTI medical events, or to individuals
hospitalized for a non-respiratory condition, many find a positive
association between RSV LRTI and subsequent RWEC with odds
ratios ranging from 3 to 36 [35,37,43–52] and between RSV LRTI
and asthma with odds ratios ranging from 317 [35,42,53–61].
In contrast, studies that compare individuals with RSV LRTI to
those with LRTI due to other respiratory pathogens (e.g. human
rhinovirus and bocavirus) usually find no difference in the risk of
subsequent RWEC/asthma [29,31,62–74], or find RSV LRTI to be
negatively associated with these outcomes compared to the non-
RSV LRTI exposed [75–84]. Several studies compared the same
exposure group (with RSV LRTI medical events) to both types of
comparison groups and found a positive association between RSV
LRTI and RWEC/asthma when comparing exposed individuals to
those without LRTI, but no significant association when compared
to those with a non-RSV LRTI [37,42,53,54,76,77,85–89]. These
studies suggest that LRTI due to some other respiratory viruses is
as, or possibly more likely, to result in RWEC/asthma than RSV
LRTI.
The second type of prospective study is a birth cohort study in
which participants are enrolled in early infancy and prospectively
surveilled for respiratory illnesses and RWEC/asthma outcomes.
These include high-risk birth cohorts that enroll infants born pre-
term and/or with a family history of asthma or atopy [21,90–92]
as well as cohorts of healthy, term infants [93–96]. Most compare
children with RSV LRTI to those without LRTI of any type; some
report positive associations with RWEC/asthma [91–93,95,97]
and others find no association [21,90,94,98]. Those that compare
risk of RWEC/asthma in children with RSV LRTI compared to those
with a non-RSV LRTI have foundmixed results [96] or no difference
in risk between LRTI groups with respect to future RWEC/asthma
[99,100].
A third type of prospective observational study follows non-
randomized infants who received RSV mAbs [101–108] or RSV
immunoglobulin [103] based on clinical indications and compares
RWEC and asthma outcomes in this group to children with similar
clinical profiles who did not receive RSV immunoprophylaxis.
Some of these studies showed a reduction in RWEC in preschool
aged children but no effect on outcomes measured at older ages
[101,102,106], one found a reduction in RWEC in nonatopic but
not in atopic children [104], and others found no difference in
asthma by treatment status [107,108].
The association between RSV and RWEC/asthma can also be
evaluated retrospectively, using administrative databases such as
medical records. Administrative database studies have consistently
shown associations between RSV LRTI hospitalization or unspeci-
fied bronchiolitis in early life and RWEC/asthma medical events
in later life [32,109–113], although only one such study required
laboratory confirmation of RSV [111]. A study of children with pri-
mary RSV LRTI hospitalization before 24 months of age found that
rates of subsequent asthma hospitalizations were approximately
4-fold higher in children first hospitalized with RSV LRTI between
6 and 24 months of age compared to children first hospitalized
with RSV LRTI between 0 and 3 months of age [110]. A twin data-
base in Denmark showed no difference in asthma or lung function
among monozygotic twins discordant for RSV hospitalization in
early life [39–41].
5.2. Randomized intervention studies
Two placebo-controlled randomized controlled trials (RCTs) of
RSV mAbs have assessed RWEC and/or asthma outcomes. The first
trial was an RCT of palivizumab conducted in healthy preterm
Dutch infants that showed a decrease in the number of days
with parent-reported wheezing in the first year of life and
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parent-reported current asthma at six years of age in the interven-
tion group, but no difference in physician-diagnosed asthma or
lung function at six years of age [114,115]. The second trial was
an RCT of motavizumab, an efficacious next generation mAb that
ultimately was not pursued for licensure. The motavizumab trial
was conducted in healthy, term Native American infants and found
no difference between treatment groups in the incidence of medi-
cally attended wheezing between one and three years of age [116].
5.3. Systematic reviews of the available evidence
Several systematic reviews [37,117–119] and two meta-
analyses [120,121] have assessed the evidence for an association
between RSV illness and subsequent RWEC and/or asthma. The
most recent systematic review without meta-analysis was pub-
lished in 2017 as a part of a series of publications from the REGAL
(RSV evidence – a Geographical Archival of the Literature) study.
It included 74 publications from the United States, Canada, and
Europe (including Turkey and the Russian Federation) [117].
Key findings were that early life RSV LRTI is strongly associated
with RWEC and asthma persisting at least through early child-
hood, and with reduced lung function and increased airway reac-
tivity. Preterm birth, Down syndrome and congenital heart
disease were identified as potential effect modifiers that increase
the strength of the association. A meta-analysis published in 2013
included 20 publications from 15 unique studies and found that
children with RSV LRTI in early life had significantly higher rela-
tive odds of wheeze and asthma in later life compared to those
without RSV LRTI (OR 3.84 [95%CI 3.23, 4.58]) [120]. A second
meta-analysis, published in 2019, included 41 observational stud-
ies and excluded immunoprophylaxis studies [121]. It found that
compared to children without respiratory symptoms in infancy,
those with laboratory confirmed RSV illness in the first year of life
had higher relative odds of RWEC through three years of age (OR
3.05 [95% CI 2.50.-3.71]) and between three and six years of age
(OR 2.60 [95% CI 1.67–4.04]). Between six and twelve years of
age, the relative odds of RWEC (OR 2.14 [95% CI 1.33–3.45])
and asthma (OR 2.95 [95% CI 1.96–4.46]) were both significantly
greater in the RSV-exposed group. When the comparator group
was infants with a non-RSV LRTI, there was no statistically signif-
icant association with subsequent RWEC or asthma for any of the
age groups and when the comparator group was infants with
human rhinovirus-associated LRTI, there was an inverse associa-
tion with RWEC between three and six years of age (OR 0.41
[95% CI 0.20–0.83]). Finally, the WHO has commissioned a third
systematic quantitative review and meta-analysis of epidemio-
logic and clinical trial data that will examine testable implications
from both causal and non-causal models for the association
between early life RSV LRTI and subsequent wheezing illness. A
limitation of all meta-analyses on this topic is that it is challeng-
ing to compare results across studies given the use of different
exposure and outcome definitions and underlying differences in
the populations being studied.
6. Methodological considerations in defining a causal
relationship between RSV LRTI and RWEC/Asthma
6.1. Observational studies
Selection bias, information bias, and confounding can each
affect observational studies of RSV and RWEC/asthma. Selection
bias can occur if children with severe RSV disease are more likely
than those with less severe RSV LRTI to be enrolled and retained
in a cohort through the study period. Information bias can occur
via differential misclassification if children with a history of RSV
LRTI are more prone to be diagnosed clinically with RWEC/asthma
and/or undergo testing for asthma, or if children in the comparator
group have RSV LRTI that is not detected. Misclassification bias can
also be introduced if parents of children with RSV LRTI are more
likely to report or remember wheezing episodes, and likewise, if
parents of children with asthma more readily recall early RSV ill-
ness. Another potential source of misclassification bias is that
many studies do not define a clear ‘washout’ period after the acute
RSV illness, raising the possibility that some wheezing associated
with the acute primary RSV disease episodes are misclassified as
respiratory sequelae.
Confounding can be another source of bias in observational
studies. Studies that do not adequately control for risk factors for
both RSV LRTI and RWEC/asthma such as age, prematurity, access
to health care, co-morbidities, exposure to indoor air pollution and
secondhand smoke, and genetic susceptibility may be subject to a
confounding bias that overestimates the association. Insufficient
understanding of the shared genetic susceptibility for RSV LRTI,
RWEC and asthma (e.g. specific immune markers or genes) limits
the possibility to control for genetic confounding in observational
designs. One approach to control for genetic confounding is to
study twins. Although their statistical power is limited by their
small size, studies of monozygotic twins discordant for RSV hospi-
talization in infancy have not shown evidence of differences in
asthma prevalence or lung function [39–41]. Another approach is
to capitalize on a quasi-random exposure variation, such as tempo-
ral variation in viral strain virulence, or periodic absences of circu-
lating RSV. A specific example of this occurs annually due to the
seasonal peaks of RSV circulation in temperate climates whereby
children born just before the RSV season are at maximal risk for
severe disease during their first few months of life when RSV circu-
lation peaks. A study in Tennessee found birth four months before
the winter virus peak to be associated with the highest risk for
developing asthma [109]. Although less prone to confounding by
a shared predisposition, birth timing studies can be confounded
by other seasonal phenomena, such as non-RSV respiratory patho-
gens, allergens and other environmental exposures.
Another consideration in interpreting observational studies is
the choice of comparison group. As noted earlier, a positive associ-
ation between RSV LRTI and subsequent RWEC/asthma is consis-
tently observed in studies that compare this exposure group to a
comparator group without any LRTI medical event, but not when
comparing to individuals with an LRTI caused by a pathogen other
than RSV. This could be interpreted as meaning that multiple res-
piratory viruses are causal agents for RWEC/asthma, that LRTI itself
is a causal agent, or that the susceptibility to develop LRTI when
infected with any respiratory virus is a marker of underlying pre-
disposition for RWEC/asthma.
Finally, although some non-randomized studies of RSV
immunoprophylaxis in high-risk infants have found a reduction
in RWEC or better lung function in treated compared to untreated
infants [101–103,105,106], the absence of randomization makes
these studies subject to biases. Moreover, the population risk pro-
files and the methods to evaluate the outcomes varied consider-
ably in these studies, making it challenging to draw inferences
across them [122]. Lastly, the restriction to high-risk infants with
a clinical indication for immunoprophylaxis limits the ability to
generalize their results to the general infant population.
6.2. Randomized controlled trials of monoclonal antibodies
The greatest advantage of RCTs is that confounding by a shared
predisposition for both the exposure and outcome should be elim-
inated. However, RCTs can be subject to misclassification bias, par-
ticularly if unmasking of the treatment assignment occurs before
the end of follow up. There may have been such bias in the Dutch
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palivizumab RCT that showed a decrease in parent-reported
asthma at six years of age after unmasking had occurred, but no
difference in more objective measures including physician-
diagnosed asthma or lung function [114].
A limitation of RCTs of RSV mAbs and vaccines is that they
require very large sample sizes to detect an association with most
RWEC/asthma outcomes. A recent analysis used systematic
reviews and expert opinions to test 81 sample size assumption sce-
narios, with risk ratios between maternal vaccination and recur-
rent wheezing ranging from 0.9 to 1.0 for 70% of the scenarios
[3]. Scenarios were ranked according to plausibility, with 75% of
plausible scenarios requiring a sample size greater than 30,000
and 47% requiring a sample size greater than 100,000 mother-
infants per trial arm. According to this analysis, the two mAb RCTs
described above, as well as a recently completed phase III maternal
RSV vaccine trial (ClinicalTrials.gov ID: NCT02624947), would have
been underpowered to find a statistically significant effect on
RWEC and asthma.
7. Recommendations for future studies
This report summarizes many of the methodologic challenges
faced by studies that aim to assess (1) whether there is a causal
association between early life RSV LRTI and subsequent RWEC
and asthma, or (2) whether an effective RSV preventive product
could be expected to reduce the risk of subsequent RWEC/asthma.
Recognizing these limitations, the participants discussed good
practices for designing and analyzing future studies in order to
maximize their contribution to the evidence base. This guidance
is presented in Tables 1A and B and summarized below:
Observational studies: Additional observational studies using
conventional designs were considered to be of little value in fur-
ther elucidating the causal link between RSV LRTI and RWEC/
asthma, with a few exceptions. Observational studies that would
be of value are those that incorporate measures of neonatal
immune function or pre-exposure lung function assessments, and
those that involve quasi-random exposure to RSV in specific geo-
graphical settings.
Randomized controlled trials: RCTs were considered to be the
least biased study design to assess both the questions of causal
association and whether RSV preventive products can reduce sub-
sequent RWEC/asthma, but they require investment in sufficiently
powered individual trials and/or the use of standardized measures
of exposure and outcome to allow pooling of data across multiple
studies for meta-analyses.
Post-introduction studies: Given the large sample sizes required
by RCTs, post-introduction studies conducted after RSV vaccines/
mAbs are licensed and introduced into national programs were
considered to be promising strategies to address these questions.
Examples include pre-post ecological studies, case-control studies,
and phased introduction studies. Pre-post studies, where
population-level rates of RWEC/asthma before and after vaccine
introduction are compared, offer a straightforward approach but
are not recommended to address these questions due to important
limitations. In addition to requiring high quality pre-introduction
surveillance data, they are susceptible to bias due to temporal
trends in disease prevalence. This is a particular risk for asthma
outcomes because asthma prevalence is not constant within com-
munities over time and secular trends in risk factors such as diet,
antibiotic use, urbanization and air pollution can be difficult to
control for [123]. Case-control studies that compare vaccination
status in children with and without the outcome of interest are
commonly used to evaluate vaccine effectiveness post-
introduction. However, such case-control studies are often biased
in that unvaccinated children differ from vaccinated children in
ways that are related to the outcome of interest; in this case their
propensity to be diagnosed with RWEC/asthma. Therefore, case-
control studies to answer this question were not considered to
be appropriate. Phased introduction, whereby a vaccine is sequen-
tially introduced to defined geographic areas, offers the most
promising design to address whether RSV preventive products
can reduce the risk of subsequent RWEC/asthma. By comparing
contemporaneous cohorts of RSV-vaccinated and unvaccinated
children, phased introduction addresses year-to-year variability
and minimizes confounding by temporal factors. Like pre-post
studies, it requires a robust surveillance system to be in place prior
to vaccine introduction and to be maintained throughout the
follow-up period. It also requires that populations with early
access to the vaccine do not differ in important ways from popula-
tions with delayed access to the vaccine (including with respect to
exposure to environmental risk factors, such as air pollution), and
that outcome ascertainment does not differ by introduction group.
In some situations, the areas for vaccine introduction can be ran-
domly assigned. Examples of this are WHO’s pilot programme for
the RTS, S/AS01 malaria vaccine [124], the phased introductions
of PCV in Mongolia [125], and hepatitis B vaccine in The Gambia
[126].
Given the limitations of each approach, a combined strategy
incorporating evidence from long-term follow up of randomized
trials in addition to post-introduction data will likely be required
to determine whether vaccines and mAbs reduce RWEC/asthma.
A challenge of all prospective study designs is retaining partici-
pants throughout the 3–5 years of follow up that are required
before outcomes can be assessed. Regardless of design, all studies
conducting long-term follow up should assess the comparability
of those who remain in the study to those who are lost to
follow-up.
Finally, the meeting participants identified key variables, defini-
tions and measurements that future studies assessing these ques-
tions should consider (Table 2). The participants recommended
that the primary exposure of interest should be laboratory-
confirmed RSV LRTI between birth and two years. Guidance for
defining the exposure was aligned with advice from a previous
WHO consultation that recommended using the Integrated Man-
agement of Childhood Illness (IMCI) definitions of LRTI [127], with
inclusion of objective measures of severity such as tachypnea and
oxygen saturation [128].
There was agreement that the primary long-term outcomes of
early life RSV LRTI that are of public health interest are RWEC, mea-
sured until at least three years of age, and asthma, measured at six
years of age or later, and that studies should prioritize medically
attended outcomes using standard definitions. FOT is a promising
tool for objective measures of lung function in infants and young
children and can be considered for use in all settings, including
LMICs [16]. In clinical trials, study personnel should remain
masked to treatment allocation for the entire duration of follow
up to minimize bias in the follow up of long-term outcomes, par-
ticularly since infants will have passed the critical age for immu-
nization once the trial has ended. Objective measures of
outcomes with blinded analysis should be prioritized.
Potential confounders are important to measure in observa-
tional studies to the extent possible but some, such as genetic sus-
ceptibility, are very difficult to control for. Simple, standardized
data collection methods for all co-variates of interest are preferred,
with birth weight, preterm birth, and family history of asthma and
atopy identified as the highest priority. Finally, although studies
are unlikely to be powered to detect effect modification, informa-
tion about preterm birth, Down syndrome, and congenital heart
disease should be collected if available.
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Table 1A
Study designs to assess a causal association between early life RSV lower respiratory tract infection and subsequent recurrent wheeze of early childhood and asthma.
Design Time required to
conduct study
Resources
required
Sample size
required
Feasible in
LMIC1 setting?
Strengths Limitations Guidance for future studies
Prospective longitudinal
cohort study (event-
based or birth cohort)
Long Medium to
high
Medium to
large
Yes & Can capture most exposure
events
& Can measure outcomes
longitudinally
& Can measure co-variates of inter-
est prospectively
& Observational, non-randomized
& Subject to biases
& Common predisposition (e.g.,
genetic confounder) cannot be
ruled out
& Loss to follow-up
& Choice of comparison group can
affect results (e.g., no LRTI vs. non-
RSV LRTI)
Additional studies using this design
offer limited potential for further
insight and should only be done (1) if
improved measurements of shared
predisposition can be measured (e.g.,
genetic markers), (2) if they assess
quasi-random exposures to RSV LRTI
(e.g., birth timing) or (3) if lung
function is measured before first RSV
exposure
Retrospective cohort
studies using
administrative data
Short Low to
medium
Large No & Large sample size available
& Can evaluate subgroups of inter-
est and effect modification
& Can be done more quickly and
with fewer resources compared
to most other designs
& Observational, non-randomized
& Imprecise definitions of exposure
and outcome are possible
& Subject to biases
& Some co-variates of interest may
not be available
Additional studies using this design
offer limited potential for further
insight and should be limited to studies
that can incorporate birth timing to
reduce bias in the exposure variable.
Randomized controlled
trials or vaccine probe
studies
Long High Large Yes & Randomized exposure
& Standardized exposure and out-
come measurements make meta
analyses possible
& Can measure co-variates of inter-
est prospectively
& Very large sample size required
& Requires several years of follow up
& RSV LRTI protection period may be
limited to a few months (in the case
of maternal vaccines and mAbs)
& Definitions may be difficult to stan-
dardize in practice across different
settings
& Potential loss to follow up
This design has greater potential to
establish causal association than
observational studies. Individual
studies should be powered to assess an
RWEC/asthma outcome. If not possible,
standardized assessments should be
used so that data from multiple RCTs
can be pooled for analysis. An absence
of effect does not establish that there is
not a causal relationship. Vaccination
allocation should remain masked until
the end of long-term follow-up. If this
is not possible, a priority should be
placed on objective measurement of
outcomes with blinded analysis.
1 Low and middle-income countries
2440
A
.J.D
riscoll
et
al./V
accine
38
(2020)
2435–
2448
Table 1B
Study designs to assess whether RSV vaccines and monoclonal antibodies can reduce risk of recurrent wheeze of early childhood and asthma.
Design Time required to
conduct study
Resources
required
Sample
size
required
Feasible in LMIC1
setting?
Strengths Limitations Guidance for future studies
Randomized controlled
trials or vaccine probe
studies
Long High Large Yes & Randomized exposure
& Standardized exposure and out-
come measurements make meta
analyses possible
& Can measure co-variates of inter-
est prospectively
& Very large sample size required
& Requires several years of follow
up
& RSV LRTI protection period may
be limited to a few months (in
the case of maternal vaccines
and monoclonal antibodies)
& Definitions may be difficult to
standardize in practice across dif-
ferent settings
& Potential loss to follow up
Acceptable, with requirement for
standardized definitions to allow for
meta-analyses, and with caveat that
most individual trials will be
underpowered to find an association.
Vaccination allocation should remain
masked until the end of long-term
follow-up
Post introduction case-
control study
Short2 Medium Small-
medium
Yes & Relatively quick to conduct
& Smaller sample size needed
& Prone to bias and confounding,
particularly for multi-cause syn-
dromes like asthma
& Shared predisposition cannot be
ruled out
& Vaccination histories difficult to
reliably obtain retrospectively
Not recommended in most settings due
to high risk of confounding and bias.
Post introduction pre-post
impact study
& Post introduction
administrative database
study
Long High Large Only if surveillance
like DSS established
before introduction
& Large sample sizes are potentially
available
& Not subject to selection bias
& Ecological fallacy possible – tem-
poral trends can influence hospi-
talization and asthma rates
& Impact cannot be observed until
years after introduction
& Pre-vaccination incidence must
be established over several years
Not recommended in most settings due
to unclear temporal trends in asthma
prevalence. It is unknown whether
recurrent wheeze of early childhood is
also subject to such time-dependent
variability.
Phased introduction Long High Large Yes & Provides for a contemporaneous
comparison group
& Could be group randomized
& Comparison areas/populations
could differ in terms of temporal
trends and other confounding
factors, leading to bias
& Not feasible everywhere due to
policy constraints
& Impact cannot be observed until
years after introduction
& Potential for movement between
introduction areas resulting in
contamination of groups
Acceptable, if appropriate surveillance
is in place and if potential confounders
can be identified and adequately
controlled for.
1 Low and middle-income countries
2 A short amount of time is needed to accrue participants in case control studies, but recurrent wheeze and asthma outcomes cannot be assessed until several years after vaccination.
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8. Policy considerations
The meeting participants agreed that, given the current knowl-
edge of the potential public health benefit, RSV vaccine policy deci-
sions should be based on the efficacy and impact against the
spectrum of acute illness caused by RSV LRTI in infants and young
children, with the primary focus being prevention of severe dis-
ease. Definitive data on the impact of RSV vaccines/mAbs on sub-
sequent RWEC and asthma are unlikely to be available at the
time vaccine policy recommendations are made. If high-quality,
robust evidence does eventually support a preventive role of RSV
vaccines/mAbs for RWEC/asthma, the additional longer term
health and economic benefits related to RWEC/asthma prevention
could contribute to policy-making in some countries.
9. Summary and conclusions
This WHO-sponsored meeting was convened to evaluate the
current evidence for a causal association between RSV LRTI in
young children and subsequent development of RWEC/asthma, to
assess the potential for RSV vaccines and mAbs to reduce the risk
of RWEC and asthma, and to provide guidance for future studies
that are poised to address these questions. The evaluation of the
evidence was focused on the body of epidemiological literature
rather than the experimental data from animals and humans.
Moreover, the application of causal modelling techniques to the
epidemiologic data were not considered, but will be addressed in
the forthcoming WHO commissioned systematic review and meta-
analysis [129]. The meeting participants concluded that most
Table 2
Key variables, definitions and measurements for future studies of the association between RSV lower respiratory tract infection and subsequent recurrent wheeze of early
childhood (RWEC) and asthma.
Defining the exposure:  Exposure period
o Between birth and two years, may vary by study design
 Microbiological confirmation:
o Assays that allow for identification of RSV viral strains (A/B) are optimal
o Multiplex PCR assays should be used to identify co-infecting respiratory pathogens, when possible
o RSV gene sequencing and RSV serology at 12 months of age in conjunction with methods above are lower priority
but can be considered along with the other diagnostic methods
 Definition of lower respiratory tract infection (LRTI):
o The LRTI clinical case definition should be based on Integrated Management of Childhood Illness (IMCI) criteria
o Both LRTI inpatient and outpatient events should be included since hospitalization criteria can vary widely by
study setting
 Measures of severity:
o The following should be collected: respiratory rate, oxygen saturation, temperature, auscultation, cough, subcostal
retractions, and difficulty breast feeding/feeding
o Quantitative measures should be recorded using a continuous scale to allow for flexibility in categorization that
can be compared across settings
o A combination of these variables can be used to generate severity scores that can be compared across settings
Defining the outcome:  Measuring RWEC and asthma
o Objective measures should be prioritized, including medically attended outcomes and lung function testing
o Parent/caregiver reports can provide useful supplemental information when standardized assessments are used;
examples of Standardized Definitions include the 2019 Brighton Collaboration definitions for acute wheeze in the
pediatric population.
o In randomized trials, caregivers and physicians should be masked to treatment group allocation
o Continuous outcomes (e.g. number of medically attended wheezing events) should be reported whenever possible.
In LMIC1 settings with low literacy, phone calls are recommended over diaries. Audio and video clips can be used to
standardize reporting
o Medical costs and burden on the health system, absences from work and school, can be useful to collect depending
on the setting
 Measuring lung function
o Forced oscillation technique with bronchodilation is more sensitive than spirometry for the detection of abnormal
resistance, can be used in young children, and can be done in the field in LMIC settings
 Follow up period
o RWEC outcomes should be reported annually for each year of life, with follow up until at least three years of age
o Asthma outcomes should be assessed at six years of age or later
Potential confounders and
effect modifiers to
measure
 High priority co-variates of interest
o Birth weight, which can be a proxy for compromised lung function and development at birth
o Preterm birth, which is associated with both RSV LRTI and RWEC/asthma, but can be difficult to ascertain in LMICs
o Family history of asthma/atopy
 Additional co-variates of interest
o Co-infections with other respiratory pathogens
o Other medically attended LRTIs
o Vaccination status
o Sex
o Ethnic group
o Timing of birth relative to the RSV season
o Age at the time of first RSV LRTI illness
o Smoke exposure (including maternal smoking during pregnancy, household smoking after birth, and ambient
air pollution)
o Mode of delivery (vaginal vs. caesarean section)
o Access to health care
o Vaccination status
o Household crowding index
o Nutritional status
Subgroups of interest  Infants born preterm, with down syndrome or congenital heart disease
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observational studies show an association between RSV LRTI and
RWEC and asthma; however, the interpretation of these studies,
as they were performed, is subject to potential measured and
unmeasured biases. The most compelling counter-argument
against a causal association is that there could be a shared predis-
position for both severe RSV disease and RWEC/asthma and that
having severe disease with an RSV infection is a marker of this pre-
disposition. RCTs of RSV mAbs did not show efficacy against objec-
tive measures of RWEC/asthma, although they were not powered
to do so.
After reviewing the evidence, the participants resolved that: (i)
the current epidemiological evidence is inconclusive in establish-
ing a causal association between RSV LRTI and RWEC/asthma, (ii)
the evidence does not establish that RSV mAbs and vaccines are
likely to have a substantial effect on these outcomes and (iii) the
prevention of severe, acute RSV disease in young children, a
well-established, substantial public health burden, should con-
tinue to be the highest priority for policy-setting bodies deliberat-
ing on RSV vaccine and mAb recommendations, regardless of their
impact on subsequent RWEC and asthma (Panel 1). RSV vaccine
impact and economic models should limit prevention of RWEC/
asthma to sensitivity analyses, and RSV vaccine policy decisions
should not include impact on RWEC/asthma prevention.
Nonetheless, the participants considered that the high burden
of RWEC and asthma justifies the continued study of the associa-
tion between these two conditions, and that a better understand-
ing of the association could contribute to establishing the public
health value of RSV vaccines and mAbs. Regardless of whether a
causal association exists, the burden of RWEC/asthma in LMICs
needs to be elucidated and benchmarked to other public health
priorities. Future epidemiological studies that examine the associ-
ation should follow good practice guidance (Tables 1A and B) using
standardized methods to collect and define key variables (Table 2).
RCTs of RSV vaccines and mAbs provide the best opportunity to
probe whether a causal association exists in an unbiased way,
and such studies may consider long-term follow-up of participants
to measure RWEC, and if possible, asthma, using standardized
methods to allow for pooled analysis. Moreover, eventual large-
scale introduction of RSV preventive products might create oppor-
tunities to assess the causal association between RSV and RWEC/
asthma at a population level. The design of post-introduction eval-
uations and the development of baseline surveillance platforms
should be considered prior to introductions, particularly in LMICs
where data on the burden of RWEC/asthma are limited.
Both RSV associated LRTI and RWEC/asthma confer a substan-
tial disease burden in children globally. To identify a single inter-
vention, such an RSV vaccine or mAb, that lessens the burden of
both diseases would be a fortuitous public health success. Efforts
should continue to better understand whether this can be
achieved. Nonetheless, lack of conclusive evidence for a dual pre-
ventive impact should not slow the pursuit of new preventive
approaches independently targeting each of these important dis-
eases of childhood.
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Panel 1
Key points on the causal association between RSV lower respiratory tract infection and subsequent recurrent wheeze of early childhood (RWEC) and asthma.
RSV disease in young children
& The burden of RSV infection in young children is high, with almost all children having been exposed by age 2 years. Severe RSV illness represents a
sizeable minority of all RSV infections (15–50%).
& The prevention of severe RSV disease in young children is the primary outcome of RSV-illness prevention from a public health perspective, regard-
less of the causal association with RWEC/Asthma.
RWEC and asthma
& RWEC is common, occurring in approximately one-fifth of children. The mean global estimate of asthma prevalence at age 6–7 is approximately
11%, with wide variation by region.
& RWEC/Asthma prevalence and determinants are better understood in high income countries than low and middle income countries (LMICs). More
data are needed in LMICs to better understand the burden.
Association between RSV-LRTI and RWEC/asthma
& RSV-LRTI in infancy is associated with the later development of RWEC/asthma, though it is not known whether the association is causal.
& Severe RSV infection with lower respiratory tract involvement is more strongly associated with the development of RWEC/asthma than non-severe
RSV infection.
& RWEC and asthma are complex conditions with multiple phenotypes, and likely multiple individual and overlapping etiologies. Therefore, the frac-
tion of these outcomes that is potentially preventable by RSV vaccines/mAbs is likely to be modest, but may vary by population.
Causal association between RSV-LRTI and RWEC/asthma
& Epidemiologic studies and clinical trials present mixed evidence for a causal association between RSV infection and RWEC/asthma, which might in
part be due to different study designs, methodologies, and study populations.
& The state of current evidence is inconclusive in establishing a causal association between RSV infection and RWEC/asthma.
& RSV vaccine impact and economic models should limit prevention of RWEC/asthma to sensitivity analyses, and RSV vaccine policy decisions should
not include impacts on RWEC/asthma prevention.
& Additional high-quality evidence addressing the question of the potential for RSV vaccines/mAbs to prevent RWEC/asthma would be valuable. Such
studies should follow good practice guidance with respect to study design and the use of standardized measurements and definitions across
diverse settings.
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